What Exdensur®'s Approval Means for Severe Asthma Management

Severe eosinophilic asthma remains difficult to control for a meaningful subset of patients, even with optimized inhaled therapy. Exdensur® (depemokimab-ulaa), approved by the FDA in December 2025, adds a new option for patients ages 12 and older whose disease remains uncontrolled.

Its key differentiator is dosing: Exdensur® is administered by subcutaneous injection once every six months, the first FDA-approved ultra-long-acting biologic for severe asthma with twice-yearly dosing. For patients who struggle with adherence to more frequent biologic regimens, that interval may meaningfully change the treatment experience.

Approval was based on two Phase 3 studies, SWIFT-1 and SWIFT-2, evaluating Exdensur® as an add-on to standard therapy in patients with confirmed eosinophilic phenotype and a documented history of exacerbations. In both trials, Exdensur® significantly reduced exacerbation rates over 52 weeks compared with standard therapy alone.

As with other biologics in this class, appropriate patient selection matters. Exdensur® is not indicated for acute symptom relief, and its benefit is best established in patients with a clear eosinophilic phenotype and a documented pattern of exacerbations despite optimized inhaled therapy. For patients without that profile, the existing biologic options, Dupixent®, Xolair®, Nucala®, Fasenra®, and Tezspire®, remain better-studied alternatives.

Clinical takeaway: Exdensur®'s twice-yearly dosing may reduce treatment burden for appropriate patients, but the more important question remains patient selection. Confirm eosinophilic phenotype, document exacerbation history, and ensure inhaled controller therapy has been optimized before escalating, twice-yearly dosing is a meaningful convenience benefit, not a reason to lower the bar for biologic initiation.